Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 273.88% | 25.00% | 48.07% | -312.97% | 499.74% |
| Total Depreciation and Amortization | 0.00% | -3.23% | -40.38% | -3.70% | -3.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -350.82% | -31.16% | -24.04% | 215.63% | -283.78% |
| Change in Net Operating Assets | -67.66% | -10,593.33% | -99.08% | -25.34% | 448.56% |
| Cash from Operations | -0.45% | -84.14% | 73.09% | -442.05% | 240.65% |
| Capital Expenditure | -33.33% | 72.73% | -120.00% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -332.22% | 53.02% | 145.06% | -136.19% | 215.52% |
| Cash from Investing | -332.27% | 53.11% | 145.02% | -136.19% | 215.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -60.79% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 7.44% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 7.44% | 95.77% | -60.79% |
| Foreign Exchange rate Adjustments | 4,100.00% | 50.00% | -166.67% | 175.00% | -300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -392.19% | 63.17% | 128.88% | -164.45% | 595.06% |